Bristol Myers Squibb Co (NYSE:BMY) Sentiment Crashed to 0.94, Despite

May 16, 2018 - By Lisa Delgado

Bristol-Myers Squibb Company (NYSE:BMY) Corporate Logo

Bristol Myers Squibb Co’s Sentiment

In 2017 Q4 Bristol Myers Squibb Co (NYSE:BMY) big money sentiment decreased to 0.94, according to Securities and Exchange Commission filings. That’s down -0.09, from 2017Q3’s 1.03. 563 institutional investors started new or increased holdings, while 598 sold and trimmed stakes in Bristol Myers Squibb Co so the sentiment has worsened. These funds own 1.11 billion shares, that’s up from 1.11 billion shares in 2017Q3. Funds holding Bristol Myers Squibb Co in top 10 decreased from 45 to 36 for a decrease of 9. 72 Investors Sold All; 526 Reduced Holdings; 457 increased stakes while 106 institutional investors bought stakes.

Most Bristol Myers Squibb Co Investors

As of 2017 Q4 Terril Brothers Inc. has 9.54% invested in Bristol Myers Squibb Co. Bristol Myers Squibb Co’s shareholder Healthinvest Partners Ab owns 43,400 shares as of 2017 Q4. Sabby Management Llc reported 931,807 shares. The New Jersey-based fund Blackhill Capital Inc have invested about 5.16% of the investment manager’s stock portfolio in Bristol Myers Squibb Co. The New York-based fund Opus Point Partners Management Llc holds 90,000 shares or 4.77% of their fund portfolio.

Bristol-Myers Squibb Company discovers, develops, licenses, makes, markets, and distributes biopharmaceutical products worldwide.The firm is valued at $85.30 billion. The firm offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection .85.52 is the P/E ratio. The Company’s products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma.

Ticker’s shares touched $52.17 during the last trading session after 0.25% change.Bristol-Myers Squibb Company has volume of 3.65M shares. Since May 16, 2017 BMY has risen 11.37% and is uptrending. The stock underperformed the S&P500 by 0.18%.

On July, 26 is awaited Bristol-Myers Squibb Company (NYSE:BMY)’s earnings report, Faxor reports. Last year’s earnings per share was $0.74, while now analysts expect change of 16.22 % up from current $0.86 earnings per share. BMY’s profit could be $1.41B with 15.17 P/E in case $0.86 earnings per share is published. -8.51 % negative EPS growth is what Wall Street’s sees after $0.94 reported EPS previous quarter.

Timber Hill Limited Liability Corporation holds 0.23% of its capital in Bristol-Myers Squibb Company (NYSE:BMY) for 57,727 shs. Oregon Public Employees Retirement Fund reported 396,387 shs or 0.41% of all its holdings. Tower Bridge Advsrs has 193,519 shs. Benedict Inc invested in 16,751 shs. Mcmillion Capital Mgmt holds 62,981 shs. Hgk Asset Management holds 2.18% or 257,917 shs. Vantage Advsrs Limited Liability Company reported 0.09% of its capital in Bristol-Myers Squibb Company (NYSE:BMY). Plancorp Limited Liability, a Missouri-based fund reported 5,783 shs. Wheatland Advisors reported 28,400 shs. First Hawaiian Commercial Bank holds 0.04% or 5,339 shs. Argent Tru owns 9,042 shs. Atlantic Tru Gru Llc stated it has 0.11% in Bristol-Myers Squibb Company (NYSE:BMY). Roanoke Asset holds 1.56% or 53,100 shs in its capital. Gamco Invsts Et Al owns 408,602 shs. Johnson Fincl Inc holds 0.08% or 10,771 shs.

Bristol-Myers Squibb Company had 1 insider sale and 2 insider purchases since December 12, 2017. This’s net activity of $163,963. Paliwal Dinesh C also bought $249,948 worth of Bristol-Myers Squibb Company (NYSE:BMY) shs. $249,187 worth of Bristol-Myers Squibb Company (NYSE:BMY) was bought by Samuels Theodore R. II on Friday, December 15.

Bristol-Myers Squibb Company (NYSE:BMY) Ratings Coverage

In total 11 analysts cover Bristol Myers (NYSE:BMY). “Buy” rating has 4, “Sell” are 0, while 7 are “Hold”. (NYSE:BMY) has 36% bullish analysts. 17 are the (NYSE:BMY)’s ratings reports on 16 May 2018 according to StockzIntelligence Inc. The stock rating was maintained by Jefferies with “Hold” on Friday, April 13. On Monday, February 26 the rating was maintained by Jefferies with “Hold”. On Tuesday, April 17 the firm earned “Neutral” rating by Bank of America. On Thursday, February 15 the firm has “Overweight” rating given by Morgan Stanley. On Friday, April 27 the rating was upgraded by BMO Capital Markets to “Market Perform”. On Friday, April 20 Cowen & Co maintained Bristol-Myers Squibb Company (NYSE:BMY) with “Hold” rating. On Tuesday, February 6 the company was maintained by BMO Capital Markets. In Tuesday, February 6 report Leerink Swann maintained the stock with “Buy” rating. On Wednesday, February 28 the rating was downgraded by DZ Bank to “Hold”. On Wednesday, April 18 BMO Capital Markets maintained Bristol-Myers Squibb Company (NYSE:BMY) with “Underperform” rating.

A couple more Bristol-Myers Squibb Company (NYSE:BMY) news were published by: which released on May 01, 2018 “How Bristol-Myers Squibb’s new Peninsula digs boost its battle to beat cancer”, also on May 16, 2018 published “Nektar Therapeutics: Substantial Unlocked Value In The NKTR-358 Franchise”, the next is “Don’t Buy L Brands – Cramer’s Lightning Round (5/15/18)” on May 16, 2018. has article titled “Why Bristol-Myers Squibb Stock Crashed in April”.

Bristol-Myers Squibb Company (NYSE:BMY) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: